Skip to main content

Curia to expand US API capabilities

19th August 2021

Submitted by:

Andrew Warmington

Curia has announced plans to invest about $35 million in order to expand commercial-scale API manufacturing capacity at its largest site in Rensselaer, New York, over the course of 18 months. This is the third significant announcement in the month since the former AMRI renamed itself.

The expansion will include new vessel capacities that more than double the site’s batch-size scaling and product output. It also features new product-handling for complex small molecules, notably oncology treatments, thus enabling Curia to address growing demand for HPAPIs, while also optimising energy use and enhancing environmental standards.

“Some of the life-saving products produced at Rensselaer are highly complex,” said chairman and CEO John Ratliff. “The engineering and technology advances we have designed for the site will enhance our flexibility, efficiency and scale, allowing us to meet our customers’ current and future complex manufacturing needs.”

AMRI adopted the name Curia, taken from a Latin word for ‘purposeful assembly’, from 12 July. It said at the time that this “reinforces the company’s strategic positioning as an end-to-end global CDMO, applying its scientific expertise and extensive capabilities from R&D through to commercial manufacturing to enable its pharmaceutical and biotechnology customers to advance important new products that improve lives”.

In the following few days, Curia acquired Integrity Bio, a formulation and fill-finish company headquartered in Camarillo, California, and LakePharma, a biologics drug discovery, clinical research, development and manufacturing firm with operations in California, Massachusetts and Texas. Terms were not disclosed in either deal, but they were both integral to the rebrand, reflecting a move beyond the traditional focus on small molecules.

Ratliff said that Integrity Bio was “a great fit with our growth strategy and our existing expertise, enhancing our biologics drug product formulation development as well as our fill-finish network”. Integrity also brings West Coast coverage to Curia’s largely East Coast presence. It has facilities in Albuquerque, New Mexico; Burlington, Massachusetts; and Glasgow in Scotland.

LakePharma brought the technology platforms of cell-line development, bioexpression systems and viral vector production systems, plus relationships with 22 of the top 25 global biopharmaceutical companies. Its six facilities and 235 employees join Curia’s 21 sites and over 3,100 employees to offer end-to-end services.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington